

Impact of Obesity on Catheter Ablation of Atrial fibrillation: Patient Characteristics, Procedural Complications, Outcomes and Quality of Life

Chadi Tabaja, MD, Arwa Younis, MD, Pasquale Santageli, MD, PhD, Medhat Farwati, MD; Lorenzo Braghieri, MD; Hiroshi Nakagawa, MD, PhD, Walid I. Saliba, MD, Ruth Madden, RN; Patricia Bouscher, RN, Mohamed Kanj, MD, Thomas D. Callahan, MD, David Martin, MD, Mandeep Bhargava, MBBS, Mina Chung, MD, Bryan Baranowski, MD, Shady Nakhla, MD, Jakub Sroubek, MD, PhD, Justin Lee, MD, Tyler Taigen, MD, Patrick J. Tchou, MD, Oussama M. Wazni, MD, and Ayman A. Hussein, MD

Section of Cardiac Pacing and Electrophysiology, Heart and Vascular Institute
Cleveland Clinic, Cleveland, Ohio

Running title: Obesity and AF ablation

Word count: 3000 words

Disclosures: None related to the content of this manuscript

Corresponding author:

Ayman A. Hussein, MD

Cardiac Pacing and Electrophysiology, Heart and Vascular Institute, Cleveland Clinic

9500 Euclid Avenue, J2-2, Cleveland, OH 44195

Tel: (216) 444-6171. Fax: (216) 636-6952

Email: husseia@ccf.org

Abstract

Background: Obesity is a well-known risk factor for atrial fibrillation (AF).

Objective: To evaluate the effect of baseline obesity on procedural complications, AF recurrence, and symptoms following catheter ablation (CA).

Methods: A total of 5841 patients undergoing AF ablation (2013-2021) were enrolled in a prospectively maintained registry. Primary endpoint was AF recurrence based on electrocardiographic documentation. Patients were categorized into 5 groups according to their baseline body mass index (BMI). Patients survey at baseline and at follow-up were used to calculate AF severity score (AFSS) as well as AF burden.

Results: Major procedural complications were low (1.5%) among BMI sub-groups. At 3 years AF recurrence was highest in Class III obesity patients (48%) followed by Class II (43%), whereas Class I, normal, and overweight had similar results with lower recurrence (35%). In multivariable analyses, Class III obesity was independently associated with increased risk for AF recurrence (HR=1.30, P=0.01), whereas other groups had similar risk in comparison to normal weight. Baseline AFSS was lowest in normal weight, and highest in Obesity-III, median [interquartile range] 10 [5-16] vs 15 [10-21]. In all groups, CA resulted in improvement in their AFSS with a similar magnitude among the groups. At follow-up, AF burden was minimal and did not differ significantly between the groups.

Conclusion: AF ablation is safe with a low complication rate across all BMI groups. Morbid obesity (BMI \geq 40) was significantly associated with reduced AF ablation success. However, ablation resulted in improvement in QOL including reduction of the AFSS, and AF burden.

What is known?

- Obesity is an independent risk factor of atrial fibrillation (AF)
- Catheter ablation (CA) has emerged as a standard of care in arrhythmia management, leading to improvements in quality of life, reductions in hospitalizations, and potential reductions in major adverse clinical outcomes.
- More obese patients are being referred to catheter ablation of AF.

What is new?

- AF ablation is safe with low complication rates across all BMI sub-groups (<1.5%)
- Morbid obesity (BMI ≥ 40) was associated with increased risk of AF recurrence after ablation
- Using patient reported outcomes, AF Ablation resulted in improvement of quality of life regardless of BMI

1 **Introduction**

2 Obesity is a growing epidemic affecting nearly one third of the population worldwide.¹ It
3 is an independent risk factor for cardiovascular disease (CVD) and specifically atrial fibrillation
4 (AF).²⁻⁴ Obesity is thought to promote AF through several mechanisms; most importantly via the
5 inflammatory nature of epicardial adipose tissue, atrial remodeling and hemodynamic alterations
6 that predispose to changes in cardiac morphology.⁵ In addition, obesity-related morbid
7 conditions such as sleep apnea predispose to AF and its persistence.

8 Catheter ablation (CA) is currently widely accepted as the mainstay treatment for AF,
9 with results showing improvement in quality of life (QoL), decreased hospitalizations, and
10 potential improved cardiovascular outcomes.⁶ Along with the uptrend of obese patients being
11 referred to CA,⁷ it is important to explore the safety and efficacy of CA in such patients. Current
12 studies pertaining to the impact of obesity on ablation outcomes are inconsistent. Some studies
13 reported no impact^{8,9} while others reported reduced procedural success in obese patients.¹⁰⁻¹² On
14 the other hand, whether overweight or obese patients are more likely to develop procedure-
15 related complications from CA is still debated.^{11, 13-15} Furthermore, while it is widely accepted
16 that the primary goal of AF ablation is to relieve symptoms, the impact of obesity on QoL
17 improvement after CA is not well studied in the literature.

18 In this study, we aimed to investigate the safety, efficacy and outcomes among obese
19 patients undergoing CA for AF in a prospectively maintained registry at a tertiary care center.

20

21 **Methods**

22 *Patient population and data source*

23 The study included patients from the Cleveland Clinic AF prospective registry who
24 underwent AF CA between 2013 and 2021. All data, including but not limited to: clinical
25 variables, procedural data, complications and assessment for arrhythmia recurrences, are
26 prospectively collected in a maintained registry. In order to achieve individualized data, the
27 current study included only patients undergoing a first time ablation at our institution. A total of
28 5841 consecutive patients with available data on body mass index (BMI) were included. The
29 study was approved by the Cleveland Clinic Institutional Review Board.

30 *AF ablation protocol*

31 Our approach to AF ablation was previously described.^{16, 17} In brief, antiarrhythmic
32 medications were generally held before ablation and anticoagulants continued in an
33 uninterrupted strategy peri-procedurally. The procedures were conducted under general
34 anesthesia. Femoral venous access was obtained with ultrasound guidance. An intracardiac
35 echocardiography (ICE) probe was positioned in the right atrium to help with catheter
36 navigation, guide transseptal access to the left atrium (LA), and to monitor for procedural
37 complications. Intravenous heparin was administered before LA transseptal access and continued
38 during the procedure with a target activated clotting time (ACT) above 300 s. Three-dimensional
39 electroanatomic maps were built to guide pulmonary veins isolation in addition to real-time
40 monitoring of ablation catheter position and contact with ICE. Non-PV ablations were conducted
41 at operators' discretion. Concomitant atrial arrhythmia ablations were also performed as
42 clinically indicated. Post-procedurally, patients were monitored for complications overnight and
43 generally discharged within 24 h from procedure completion, unless longer stay was needed to
44 further manage arrhythmias, procedural complications, or diuresis.

45 *Definitions, endpoints and post-ablation follow-up*

46 Obesity was classified according to the BMI (body weight in kilograms divided by the
47 square of body height in meters) and subdivided into categories as defined by the World Health
48 Organization (WHO): the group of normal weight patients consisted of a BMI of 18.5–24.9
49 kg/m² and the overweight group had a BMI of 25–29.9 kg/m². Obesity was defined as Classes I
50 through III (BMI: 30–34.9, 35–39.9, and ≥ 40 kg/m²), respectively with Class III obesity
51 representing morbidly obese patients. Underweight patients constituted a very small percentage
52 of total patients and hence were not included in the analysis.

53 The main outcome of interest was AF free survival following the blanking period (90 days from
54 ablation). AF recurrence was defined in concordance with practice guidelines as
55 electrocardiographic documentation of AF, lasting >30 s on 12-lead ECG, Holter recording, or
56 during device interrogation of implanted devices. All clinical visits, correspondence with
57 referring doctors, phone calls, and clinical letters were included in the follow-up data. Patients
58 were provided with heart rhythm transmitters post-procedurally and instructed to transmit
59 electrocardiographic recordings whenever symptomatic and on a weekly basis even when
60 asymptomatic during the initial 3 months after ablation. Additional event recorder monitoring
61 was performed beyond the initial 3-month period in patients with documented atrial arrhythmia
62 or with symptoms suggestive of arrhythmia recurrence. Patients were also scheduled for follow-
63 up visits with 12-lead ECG at 3, 6, and 12 months, and every 6 months thereafter. Additional
64 visits were scheduled as needed for rhythm or anticoagulation management. Antiarrhythmics
65 were used as necessary during the blanking period and generally discontinued whenever possible
66 after the blanking period. Our comprehensive follow-up protocol has been described previously.
67 ^{16, 17} In addition to arrhythmia monitoring and routine clinical assessments, patient-reported
68 outcomes (PRO) were gathered at baseline and at each visit using an automated platform. For

69 PRO assessment, we included a total of 2635 who participated in the PRO surveys at baseline
70 and during follow up. The development of the PRO collection system was previously described
71 in details ^{18, 19}. This automated platform for PRO collection was developed and implemented at
72 our institution to easily collect data following AF ablation with focus on QoL metrics of patients
73 undergoing CA for AF. Patients automatically received email invitations to survey for AF-
74 specific QoL outcomes within 10 days before the ablation procedures (baseline survey), 3 and 6
75 months after the procedure and every 6 months thereafter. The automated surveys included
76 measurement of the AF Symptom Severity Scale (AFSS), a validated questionnaire for QoL
77 assessment that quantifies symptom severity using 7 symptom-related questions. A score of 0 (no
78 symptoms) to 5 (worse symptoms) is given to each question. Total scores range from 0 to 35;
79 higher scores indicate worse symptoms and a greater negative impact on QoL. In addition to the
80 AFSSS questionnaire, the automated surveys assessed AF burden (as indicated by AF frequency
81 and duration). The AF frequency score ranged from 0 (no events) to 10 (continuous persistent
82 AF). Similarly, the AF duration score ranged from 0 (no events) to 10 (continuous persistent
83 AF).

84 All complication data were prospectively collected and adjudicated. Major procedural
85 complications were defined in concordance with established guidelines as the occurrence of life-
86 threatening complications and those requiring interventions or prolongation of hospital stay.
87 These included the occurrence of cardiac tamponade, pericardial effusion requiring intervention,
88 femoral pseudoaneurysm or arteriovenous fistula requiring intervention, bleeding requiring blood
89 transfusion, hematoma requiring drainage, persistent phrenic nerve palsy, pulmonary vein
90 stenosis (PVS), atrio-esophageal fistula, transient ischemic attack (TIA) or stroke, or death. Early
91 readmissions or mortality within the first 4 weeks after ablation were also assessed.

92 *Statistical analyses*

93 Continuous variables are expressed as mean \pm SD. Categorical data are summarized as
94 numbers (percent). Baseline clinical characteristics and complications were presented for each
95 BMI group. The groups were compared with the use of the analysis of variance (ANOVA) or
96 Wilcoxon ranked sum test for continuous variables; as appropriate, and χ^2 test for categorical
97 variables. Freedom from AF by different groups at baseline was displayed by tracing the
98 Kaplan-Meier curves, with comparisons of cumulative event rates by the log-rank test.

99 To confirm associations determined by unadjusted analyses, adjusted Cox proportional hazards
100 regression analysis was used to predict the associated risk in each BMI group when compared
101 with normal weight group. The proportional hazards assumption was tested and met. Candidate
102 covariates for the models are defined in **Supplementary Table**. Final model covariates were
103 determined with the use of a stepwise selection process and were included if statistically
104 significant at $p < 0.05$ for the primary end point. The final proportional hazard regression models
105 were adjusted for gender, age, AF type (paroxysmal or persistent), prior ablation, prior use of
106 antiarrhythmic drugs (AADs), use of Cryoballoon and posterior wall isolation.

107 All statistical tests were 2 sided, and a P value of < 0.05 was considered to be statistically
108 significant. Analyses were carried out with the use of SAS software (version 9.4; SAS Institute,
109 Cary, NC).

110

111 **RESULTS**

112 *Baseline characteristics and procedural complications*

113 A total of 5841 patients were included (17% normal weight, 34% overweight, 27% Class
114 I, 13% Class II and 9% Class III). Their baseline characteristics are summarized in **Table 1**. The
115 mean age of the overall patient population was 64 ± 10 years and 66% were male. Obese patients
116 were statistically younger than non-obese patients (64 ± 9.8 , 64 ± 9.1 and 61.1 ± 9.7 years for Class I
117 through III vs 65 ± 10 and 66 ± 11 years in normal and overweight respectively, $P < 0.001$). Atrial
118 fibrillation was paroxysmal in 47% (PAF) and persistent in 53% (PersAF). An inverse
119 relationship was observed between AF type and BMI. Normal weight patients were more likely
120 to have paroxysmal AF (57%) whereas the rate in obesity Class III was significantly lower (38%,
121 $P < 0.05$). The prevalence of coronary and cerebrovascular disease risk factors such as
122 hypertension, diabetes mellitus and heart failure were increasingly higher in overweight, obese
123 and morbidly obese patients ($P < 0.001$). The prevalence of atrial flutter decreased with increasing
124 BMI ($P < 0.001$). Valvular heart disease was present in 13.6% of patients at baseline.

125 The procedural complication rates were low ($< 1.5\%$) and were similar in all groups ($p > 0.05$). A
126 breakdown of procedure related complications in BMI subgroups is provided in **Table 2**.

127 *Arrhythmia ablation outcomes and QOL by BMI type*

128 During a mean follow up of 15 ± 9 months, a total of 1533 patients (26%) had at least one
129 episode of AF following their blanking period. **Figure 1** shows the Kaplan-Meier curves for
130 freedom from AF by BMI groups. Upon 3 years of follow-up, the rate of AF recurrence for all
131 BMI groups $< 35 \text{ kg/m}^2$ ranged between 35 and 37%. The rate of AF recurrence was significantly
132 higher in patients with $\text{BMI} \geq 35 \text{ kg/m}^2$ (Class II: 43%, Class III: 48%, $P < 0.05$).

133 Unadjusted Cox proportional hazards analyses were performed to assess the association
134 of different BMI groups with AF recurrence (normal BMI used as reference) (**Table 3**). Before

135 adjustment, only obesity Class III group (morbidly obese) was at increased risk of AF recurrence
136 (HR= 1.30; 95% confidence interval [CI], 1.10-1.53, P=0.02) compared to normal BMI. In the
137 adjusted model; which accounted for covariates that were found to have significant associations
138 with AF recurrence in unadjusted analyses, Class III obesity was found to have an independent
139 association with AF recurrence (HR=1.30, CI, 1.06-1.59, P=0.012). No significance difference
140 was observed between the remaining BMI groups and those with normal BMI (overweight
141 HR=0.98, Class I HR=0.98, Class II HR=1.16, P>0.05).

142 *Quality of Life*

143 A total of 2635 patients participated in the automated surveys. In terms of PRO, there
144 was a positive correlation between BMI and AFSS such as baseline AFSS was lowest in normal
145 weight and overweight groups (median [interquartile range] AFSS was 10 [5-16]), and
146 increasingly higher with higher obesity class (highest in obesity Class III, median [interquartile
147 range] AFSS was 15 [10-21]; P<0.001). Upon follow-up, CA resulted in significant reduction in
148 AFSS among all groups (median [interquartile range] normal weight 10 [5-16] vs 2 [0-7];
149 overweight 10 [5-16] vs. 3 [0-7]; Class I obesity 12 [7-18] vs 3 [0-8] Class II obesity 13.5 [8-19]
150 vs 4 [1-10] and Class III obesity 15 [10-21] vs 5 [2-10]; P<0.05 for each comparison) (**Figure2**).

151 Similarly, AF burden scores were significantly reduced across all groups. The median
152 AF duration score follow-up post-ablation was significantly lower than the median at baseline
153 (median [interquartile range] normal weight 6.25 [5.62-8.75] vs 0 [0-2.5]; overweight 6.25 [6.25-
154 10] vs. 0 [0-2.5]; Class I obesity 7.5 [7-10] vs 0 [0-2.5]; Class II obesity 8.75 [6.25-10] vs 0 [0-
155 3.75] and Class III obesity 8.75 [6.25-10] vs 0 [0-3.75]; P<0.01 for each comparison) . Similar
156 results were obtained AF frequency score normal weight 7 [4-9] vs 0 [0-3]; overweight 7 [5-9]

157 vs. 0 [0-2]; Class I obesity 8 [5-10] vs 0 [0-2]; Class II obesity 8 [5-10] vs 0 [0-2] and Class III
158 obesity 8 [5-10] vs 0 [0-3]; P<0.05 for each comparison) (**Figure 3**)

159 In a subset, we further analyzed AF burden selectively in patients who had AF recurrence
160 within during follow up (N=799) of CA and compared to baseline. Both AF duration score and
161 AF frequency score were significantly reduced among patients with AF recurrence (median
162 [interquartile range] AF duration score: normal weight 8 [4-10] vs 3 [2-7]; overweight 7.5[6.25-
163 10] vs. 6.25 [2.5-8.75]; Class I obesity 8.75 [6.25-10] vs 6.25 [2.5-8.75]; Class II obesity 8.75
164 [6.25-10] vs 7.25 [6.25-10] and Class III obesity 8.75 [6.25-10] vs 6.25 [1.25-8.75]; median
165 [interquartile range] AF frequency score: normal weight 7 [4-9.5] vs 3 [2-7]; overweight 8 [4-10]
166 vs. 3 [2-7]; Class I obesity 8 [5-10] vs 3 [2-6]; Class II obesity 8 [5-10] vs 4 [2-8] and Class III
167 obesity 9 [6-10] vs 4 [2-7.5]). (**Figure 3**)

168

169 **Discussion**

170 In this prospective large cohort of patients undergoing CA for AF at a tertiary care center,
171 we assessed the impact of obesity on procedural safety, outcomes and QOL. The main findings
172 of the study are the following: 1) Patients with higher BMI have higher prevalence of
173 comorbidities including hypertension, diabetes mellitus and heart failure and worse AFSS at
174 baseline; 2) The safety profile of CA in the obese population is acceptable with similarly low
175 complication rates among all BMI groups when compared to normal weight; 3) Class III obesity
176 was independently associated with increased AF recurrence in adjusted analyses; 4) CA resulted
177 in significant improvement in QoL and reduction in AF burden regardless of BMI group. To our

178 knowledge this is the largest single-center cohort to investigate the impact of BMI on procedural
179 outcomes, safety and QOL.

180 Catheter ablation has become standard of care in the management of AF, with excellent
181 safety profiles; as demonstrated in this cohort from a tertiary care center. Importantly, our study
182 showed that obesity did not increase the risk of AF ablation procedure-related complications. An
183 important factor which could have contributed to this is obtaining vascular access with
184 ultrasound in all patients²⁰ and the experience in the current report being from a high volume
185 center. These data are in contrast with higher rates of complications reported from two large real-
186 world nationwide inpatient sample studies^{21, 22} which evaluated the impact of obesity on CA in
187 more than 100,000 patients. Our data are in line with other studies which found no added
188 procedure related risks in obese patients;^{8, 13, 14, 23} even in morbidly obese which were previously
189 reported to have higher complication rates.²⁴

190 In terms of clinical outcomes, published studies have produced conflicting findings on
191 the association of obesity and arrhythmia recurrences after ablation. In the current report, only
192 morbid obesity was independently associated with AF recurrence and in association with higher
193 rates of persistent AF; potentially reflecting more advanced atrial myopathy, altered
194 neuromodulation and hemodynamic strain.²⁵ Our results are consistent with prior reports, yet
195 with minor nuances. Winkle et al.²⁴ divided 2715 AF patients undergoing ablation by BMI and
196 reported a cut-off value of 35 kg/m², beyond which BMI was found to have a negative impact on
197 ablation outcomes. It is possible that such observation is primarily driven by BMI \geq 40 kg/m², as
198 suggested by our findings. The same could apply to another study by Glover et al.²⁶ which
199 studied the impact of BMI on AF ablation outcomes in 3333 patients, categorized into 3 groups
200 (BMI < 25, BMI: 25.5–29, and BMI \geq 30) and showed worse outcomes for patients with

201 BMI \geq 30 kg/m². Urbanek et al.¹⁰ investigated to role of cryoballoon ablation in obese patients
202 with symptomatic AF and found that procedural success was reduced for patients with BMI>35
203 kg/m². Another study by Sivasambu et al.²⁷ showed being overweight (BMI \geq 25 to < 30)
204 increased arrhythmia recurrence compared to normal weight patients. To be noted that the
205 studies that did not find an association between obesity and ablation outcomes were limited by
206 the fact that they combined all obese patients into a single category (>25 or >30) and included a
207 smaller number of patients with short term follow-up.^{8,28}

208 While our findings indicate that ablation success is reduced with morbid obesity, it is
209 unclear whether or not weight loss implementation as a pre-requisite before ablation would affect
210 the outcomes. The recent SORT-AF²⁹ trial randomized patients with a BMI between 30 and 40
211 kg/m² who underwent AF-ablation to usual care or weight reduction with a goal to evaluate the
212 effect of weight loss on the success rate of AF ablation in obese patients. After ablation, AF
213 burden did not differ between the two groups. Importantly, there was a significant decrease in
214 AF burden among all BMI groups; in line with our study findings. Even though pre-procedural
215 weight loss can have significant health benefits on morbidly obese patients undergoing ablation,
216 it may be difficult to achieve in this group of patients who suffer from high AF burden and
217 limited exercise capability. We suggest that AF ablation can still be performed in morbidly obese
218 patients with the goal of reducing AF burden and improving QOL; while considering a formal
219 weight management program and possibly bariatric surgery, as applicable.

220 **Limitations**

221 The limitations of observational studies apply to the findings in this cohort, including the
222 possibility of confounding from referral bias caused by patient selection. That being said, the
223 study reflects real world clinical practice and data were collected prospectively. Another

224 limitation pertains to asymptomatic AF recurrences which applies to most AF ablation studies.

225 Nonetheless, AF ablation procedures are typically performed with the goal of improving QOL.

226 The study showed a significant QOL benefit in all patients and regardless of BMI.

227 **Conclusion**

228 In this cohort of AF patients undergoing ablation at a tertiary care center, complication
229 rates were low and similar across BMI sub-groups. Morbid obesity with a BMI 40 kg/m^2 was
230 significantly associated with reduced AF ablation success. However, ablation resulted in
231 improvement in QOL including reduction of the AFSS, and both duration and frequency of AF
232 regardless of BMI. While it is reasonable to recommend AF ablation to symptomatic patients
233 regardless of their BMI, the overall benefits of weight loss should not be overlooked.

234

References:

1. Ataey a, jafarvand e, adham d and moradi-asl e. The relationship between obesity, overweight, and the human development index in world health organization eastern mediterranean region countries. *Journal of preventive medicine and public health*. 2020;53:98 - 105.
2. Swinburn ba, sacks g, hall kd, mcpherson k, finegood dt, moodie ml and gortmaker sl. The global obesity pandemic: shaped by global drivers and local environments. *The lancet*. 2011;378:804-814.
3. Czernichow s, kengne ap, stamatakis e, hamer m and batty gd. Body mass index, waist circumference and waist-hip ratio: which is the better discriminator of cardiovascular disease mortality risk? Evidence from an individual-participant meta-analysis of 82864 participants from nine cohort studies. *Obesity reviews*. 2011;12:680-687.
4. Singh gm, danaei g, farzadfar f, stevens ga, woodward m, wormser d, kaptoge s, whitlock g, qiao q, lewington s, di angelantonio e, vander hoorn s, lawes cmm, ali mk, mozaffarian d, ezzati m, global burden of metabolic risk factors of chronic diseases collaborating g, asia-pacific cohort studies c, diabetes epidemiology: collaborative analysis of diagnostic criteria in e, emerging risk factor c and prospective studies c. The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: a pooled analysis. *Plos one*. 2013;8:e65174.
5. Lavie cj, pandey a, lau dh, alpert ma and sanders p. Obesity and atrial fibrillation prevalence, pathogenesis, and prognosis: effects of weight loss and exercise. *Journal of the american college of cardiology*. 2017;70:2022-2035.
6. Turagam mk, musikantow d, whang w, koruth js, miller ma, langan mn, sofi a, choudry s, dukkipati sr and reddy vy. Assessment of catheter ablation or antiarrhythmic drugs for first-line therapy of atrial fibrillation: a meta-analysis of randomized clinical trials. *Jama cardiol*. 2021;6:697-705.
7. Prasitlumkum n, chokesuwattanaskul r, kaewput w, thongprayoon c, bathini t, boonpheng b, vallabhajosyula s, cheungpasitporn w and jongnarangsin k. Utilization and in-hospital complications of catheter ablation for atrial fibrillation in patients with obesity and morbid obesity. *Clinical cardiology*. 2022;45:407-416.
8. Cha y-m, friedman pa, asirvatham sj, shen w-k, munger tm, rea rf, brady pa, jahangir a, monahan kh, hodge do, meverden ra, gersh bj, hammill sc and packer dl. Catheter ablation for atrial fibrillation in patients with obesity. *Circulation*. 2008;117:2583-2590.
9. Jongnarangsin k, chugh a, good e, mukerji s, dey s, crawford t, sarrazin jf, kuhne m, chalfoun n, wells d, boonyapisit w, pelosi j, frank, bogun f, morady f and oral h. Body mass index, obstructive sleep apnea, and outcomes of catheter ablation of atrial fibrillation. *Journal of cardiovascular electrophysiology*. 2008;19:668-672.
10. Urbanek l, bordignon s, chen s, bologna f, tohoku s, dincher m, schulte-hahn b, schmidt b and chun k-rj. Impact of body mass index on cryoablation of atrial fibrillation: patient characteristics, procedural data, and long-term outcomes. *Journal of cardiovascular electrophysiology*. 2022;33:1106-1115.
11. Sivasambu b, balouch ma, zghaib t, bajwa rj, chrispin j, berger rd, ashikaga h, nazarian s, marine je, calkins h and spragg dd. Increased rates of atrial fibrillation recurrence following pulmonary vein isolation in overweight and obese patients. *Journal of cardiovascular electrophysiology*. 2018;29:239-245.

12. Mohanty s, mohanty p, di biase l, bai r, dixon a, burkhardt d, gallinghouse jg, horton r, sanchez je, bailey s, zagrodzky j and natale a. Influence of body mass index on quality of life in atrial fibrillation patients undergoing catheter ablation. *Heart rhythm*. 2011;8:1847-1852.
13. Schenker n, von blumenthal f, hakmi s, lemes c, mathew s, rottner l, wohlmuth p, reimann b, rillig a, metzner a, willems s, ouyang f, kuck k-h and maurer t. Impact of obesity on acute complications of catheter ablation for cardiac arrhythmia. *Journal of cardiovascular electrophysiology*. 2022;33:654-663.
14. Glover bm, hong kl, dagres n, arbelo e, laroche c, riahi s, bertini m, mikhaylov en, galvin j, kiliszek m, pokushalov e, kautzner j, calvo n, blomstrm-lundqvist c and brugada j. Impact of body mass index on the outcome of catheter ablation of atrial fibrillation. *Heart*. 2019;105:244.
15. Providncia r, adrago p, de asmundis c, chun j, chierchia g, defaye p, anselme f, creta a, lambiase pd, schmidt b, chen s, cavaco d, hunter rj, carmo j, combes s, honarbakhsh s, combes n, sousa mj, jebberi z, albenque jp and boveda s. Impact of body mass index on the outcomes of catheter ablation of atrial fibrillation: a european observational multicenter study. *J am heart assoc*. 2019;8:e012253.
16. Kanj m, wazni o and natale a. Pulmonary vein antrum isolation. *Heart rhythm*. 2007;4:s73-9.
17. Bassiouny m, saliba w, hussein a, rickard j, diab m, aman w, dresing t, callahan tt, bhargava m, martin do, shao m, baranowski b, tarakji k, tchou pj, hakim a, kanj m, lindsay b and wazni o. Randomized study of persistent atrial fibrillation ablation: ablate in sinus rhythm versus ablate complex-fractionated atrial electrograms in atrial fibrillation. *Circ arrhythm electrophysiol*. 2016;9:e003596.
18. Hussein aa, lindsay b, madden r, martin d, saliba wi, tarakji kg, saqi b, rausch dj, dresing t, callahan t, chung mk, baranowski b, bhargava m, cantillon d, rickard j, kanj m, tchou p, wilkoff bl, nissen se and wazni om. New model of automated patient-reported outcomes applied in atrial fibrillation. *Circulation arrhythmia and electrophysiology*. 2019;12:e006986.
19. Farwati m, wazni om, tarakji kg, diab m, scandinaro a, amin m, zmaili m, bazarbashi n, dikilitas o, nakagawa h, kuroda s, kanj m, dresing tj, callahan td, bhargava m, baranowski b, rickard j, cantillon dj, tchou pj, saliba wi and hussein aa. Super and nonresponders to catheter ablation for atrial fibrillation: a quality-of-life assessment using patient reported outcomes. *Circ arrhythm electrophysiol*. 2021;14:e009938.
20. Yamagata k, wichterle d, roubcek t, jarkovsky p, sato y, kogure t, peichl p, konecny p, jansova h, kucera p, aldhon b, cihk r, sugimura y and kautzner j. Ultrasound-guided versus conventional femoral venipuncture for catheter ablation of atrial fibrillation: a multicentre randomized efficacy and safety trial (ultra-fast trial). *Europace*. 2018;20:1107-1114.
21. Prasitlumkum n, chokesuwattanaskul r, kaewput w, thongprayoon c, bathini t, boonpheng b, vallabhajosyula s, cheungpasitporn w and jongnarangsin k. Utilization and in-hospital complications of catheter ablation for atrial fibrillation in patients with obesity and morbid obesity. *Clin cardiol*. 2022;45:407-416.
22. D'souza s, elshazly mb, dargham sr, donnellan e, asaad n, hayat s, kanj m, baranowski b, wazni o, saliba w and abi khalil c. Atrial fibrillation catheter ablation complications in obese and diabetic patients: insights from the us nationwide inpatient sample 2005–2013. *Clinical cardiology*. 2021;44:1151-1160.
23. Providncia r, adrago p, de asmundis c, chun j, chierchia g, defaye p, anselme f, creta a, lambiase pd, schmidt b, chen s, cavaco d, hunter rj, carmo j, combes s, honarbakhsh s, combes n, sousa mj, jebberi z, albenque jp and boveda s. Impact of body mass index on the outcomes of catheter ablation of atrial fibrillation: a european observational multicenter study. *Journal of the american heart association*. 2019;8:e012253.
24. Winkle ra, mead rh, engel g, kong mh, fleming w, salcedo j and patrawala ra. Impact of obesity on atrial fibrillation ablation: patient characteristics, long-term outcomes, and complications. *Heart rhythm*. 2017;14:819-827.

25. Dublin s, french b, glazer nl, wiggins kl, lumley t, psaty bm, smith nl and heckbert sr. Risk of new-onset atrial fibrillation in relation to body mass index. *Archives of internal medicine*. 2006;166:2322-2328.
26. Glover bm, hong kl, dagres n, arbelo e, laroche c, riah s, bertini m, mikhaylov en, galvin j, kiliszek m, pokushalov e, kautzner j, calvo n, blomström-lundqvist c and brugada j. Impact of body mass index on the outcome of catheter ablation of atrial fibrillation. *Heart*. 2019;105:244-250.
27. Sivasambu b, balouch ma, zghaib t, bajwa rj, chrispin j, berger rd, ashikaga h, nazarian s, marine je, calkins h and spragg dd. Increased rates of atrial fibrillation recurrence following pulmonary vein isolation in overweight and obese patients. *J cardiovasc electrophysiol*. 2018;29:239-245.
28. Jongnarangsin k, chugh a, good e, mukerji s, dey s, crawford t, sarrazin jf, kuhne m, chalfoun n, wells d, boonyapisit w, pelosi jf, bogun f, morady f and oral h. Body mass index, obstructive sleep apnea, and outcomes of catheter ablation of atrial fibrillation. *Journal of cardiovascular electrophysiology*. 2008;19:668-672.
29. Gessler n, willems s, steven d, aberle j, akbulak ro, gosau n, hoffmann ba, meyer c, sultan a, tilz r, vogler j, wohlmuth p, scholz s, gunawardene ma, eickholt c and lüker j. Supervised obesity reduction trial for af ablation patients: results from the sort-af trial. *Ep europace*. 2021;23:1548-1558.

Table 1- Clinical baseline characteristics according to body mass index categories

Clinical Characteristics	Normal Weight	Overweight	Class I Obesity	Class II Obesity	Class III Obesity
	BMI 18.5–24.9 kg/m ²	BMI 25–29.9 kg/m ²	BMI: 30–34.9 kg/m ²	BMI 35–39.9 kg/m ²	BMI ≥40 kg/m ²
Number of Patients	986	1997	1596	758	504
Age at enrollment	66±11.4	65±10.0 ^a	64±9.8 ^b	64±9.1 ^c	61.1±9.7 ^d
Male	578 (59%)	1552 (78%) ^a	1212 (76%) ^b	530 (70%) ^c	282 (56%)
Black	10 (1%)	33 (2%)	46 (3%) ^b	30 (4%) ^c	23 (5%) ^d
BMI, kg/m²	23±1.6	27.5±1.4 ^a	32.2±1.4 ^b	37±1.4 ^c	44±6.5 ^d
Smoking	260 (36%)	560 (42%) ^a	456 (40%)	234 (45%) ^c	140 (40%)
Paroxysmal	562 (57%)	1005 (50%) ^a	707 (44%) ^b	284 (37%) ^c	190 (38%) ^d
Atrial Flutter	254 (26%)	438 (22%) ^a	297 (19%) ^b	132 (17%) ^c	83 (16%) ^d
Prior AF Ablation	325 (33%)	668 (33%)	531 (33%)	244 (32%)	156 (31%)
Prior Cardioversion	190 (27%)	475 (35%) ^a	459 (41%) ^b	252 (48%) ^c	153 (44%) ^d
Cryoballoon	97 (10%)	218 (11%)	185 (12%)	86 (11%)	54 (11%)
Posterior Wall	781 (79%)	1552 (78%)	1203 (75%) ^b	596 (79%)	418 (83%)
LVEF, %	56.0±10.3	55.5±10.0	55.3±10.0 ^b	54.1±11.1 ^c	54.4±10.0 ^d
LA Diameter, mm	3.9±0.8	4.2±0.7 ^a	4.4±0.7 ^b	4.6±0.7 ^c	4.5±0.7 ^d
CHA²DS²VASc	2.8±1.5	2.6±1.4 ^a	2.7±1.5	2.9±1.5 ^c	2.8±1.5 ^d
0-2,	540 (55%)	1207 (60%) ^a	907 (57%)	374 (49%) ^c	247 (49%) ^d
≥3,	446 (45%)	790 (40%) ^a	689 (43%)	384 (51%) ^c	257 (51%) ^d
Heart Failure	171 (17%)	382 (19%)	338 (21%) ^b	201 (27%) ^c	132 (26%) ^d
Hypertension	443 (45%)	1080 (54%) ^a	1065 (67%) ^b	570 (75%) ^c	387 (77%) ^d
Diabetes	69 (7%)	185 (9%) ^a	292 (18%) ^b	217 (29%) ^c	156 (31%) ^d
Stroke/TIA	53 (5%)	90 (5%)	61 (4%) ^b	43 (6%)	27 (5%)
Valvular Disease	188 (19%)	271 (14%) ^a	194 (12%) ^b	97 (13%) ^c	48 (10%) ^d
Prior PCI	59 (6%)	142 (7%)	148 (9%) ^b	67 (9%) ^c	49 (10%) ^d
COPD	55 (6%)	84 (4%)	76 (5%)	60 (8%) ^c	36 (7%)
DVT or PE	5 (1%)	15 (1%)	10 (1%)	10 (1%) ^c	5 (1%)
Malignancy	62 (6%)	105 (5%)	81 (5%)	39 (5%)	22 (4%)
ICD	50 (5%)	94 (5%)	75 (5%)	38 (5%)	28 (6%)
Antiarrhythmic	692 (70%)	1413 (71%)	1189 (74%) ^b	559 (74%)	383 (76%) ^d
Beta-blocker	466 (47%)	1066 (53%)	902 (57%)	435 (57%)	292 (58%)

^{a b c d} Represents statistically significant results (P<0.05) when compared with normal weight

Abbreviations: BMI: Body Mass Index, LVEF: Left Ventricular Ejection Fraction, TIA: Transient Ischemic Attack, COPD: Chronic Obstructive Pulmonary Disease, DVT: Deep Vein Thrombosis, PE: Pulmonary Embolism, ICD:

Implantable Cardioverter-Defibrillator, LAAO: Left Atrial Appendage Occlusion, CVA: Cerebral Vascular, PCI: percutaneous intervention

Table 2 – Major procedural complications according to BMI group

Clinical Characteristics	Normal	Overweight	Class I Obesity	Class II Obesity	Class III Obesity	Total
Number of Patients, #	986	1997	1596	758	504	5841
Vascular or Bleeding	3(0.3%)	2(<0.1%)	5(0.3%)	3(0.4%)	2(0.4%)	15
Pulmonary Vein Stenosis	3(0.3%)	12(0.6%)	9(0.5%)	2(0.3%)	0	26
Phrenic Nerve Injury	1(0.1%)	7(0.3%)	3(0.2%)	2(0.3%)	3(0.6%)	16
Esophageal Fistula	1(0.1%)	0	0	2(0.3%)	0	3
Pericardial Effusion	6(0.6%)	5(0.2%)	4(0.2%)	3(0.4%)	1(0.2%)	19
CVA or TIA	2(0.2%)	1(0.05%)	0	2(0.3%)	0	5
Death within 30 Days	1(0.1%)	1(0.05%)	0	1(0.1%)	0	3
Total	17(1.7%)	28(1.4%)	21(1.3%)	15(1.9%)	6(1.1%)	87(1.5%)

Abbreviations: CVA: Cerebral Vascular Event, TIA: Transient Ischemic Attack.

Figure 1- Kaplan–Meier curves showing rates of atrial fibrillation-free survival over time in normal weight (blue), overweight (red), and obesity classes: I (green), II (brown) and III (purple) subjects.




Table 3 – Cox proportional hazards analyses assessing the association of BMI groups and recurrent arrhythmia after ablation

Group	No. of Patients	No. of Events	HR	95% CI	p value
Unadjusted Analyses					
Normal BMI	986	254	Reference		
Overweight	1997	510	0.915	0.82-1.02	0.10
Class I Obesity	1596	398	0.94	0.83-1.05	0.25
Class II Obesity	758	213	1.14	0.99-1.32	0.07
Class III Obesity	504	155	1.30	1.10-1.53	0.002
Adjusted Analyses					
All Patients					
Normal BMI			Reference		
Overweight			0.98	0.86-1.16	0.98
Class I Obesity			0.98	0.84-1.15	0.84
Class II Obesity			1.16	0.96-1.40	0.12
Class III Obesity			1.30	1.06-1.59	0.01

Figure 2: Atrial Fibrillation Symptom Severity Score according to BMI groups





Figure 3: Atrial Fibrillation Duration and Frequency Scores in the entire study cohort and in those with arrhythmia recurrence







Impact of Obesity on Catheter Ablation of Atrial fibrillation: Patient Characteristics, Procedural Complications, Outcomes and Quality of Life

**Prospective AF ablation
(2013-2021)**

**Study population
5841 consecutive patients
presenting for AF ablation**




Population stratified by BMI (kg/m²)
 Normal (18.5-24.9)
 Overweight (25-29.9)
 Obesity Class I (30-34.9)
 Obesity Class II (35-39.9)
 Obesity Class III (≥40)



Conclusions

- AF ablation is safe with low complication rates across all BMI sub-groups (<1.5%)
- Morbid obesity (BMI ≥40) was associated with increased risk of AF recurrence after ablation
- Using patient reported outcomes, AF Ablation resulted in improvement of quality of life regardless of BMI




Normal ——— Overweight — — — — Class I ——— Class II ——— Class III — — — —

Normal	844	554	294	226	139	137
Overweight	1709	1154	661	485	315	308
Class I	1335	875	519	373	234	229
Class II	624	405	210	138	80	77
Class III	418	256	140	98	59	56

Atrial Fibrillation Symptoms Severity Score (AFSS)

Entire study Cohort (N=2635)

P<0.05



Normal

Overweight

Class I Obesity

Class II Obesity

Class III Obesity

BMI 18.5–24.9

BMI 25–29.9


BMI 30–34.9

BMI 35–39.9


BMI >40

Baseline Follow up


AF Duration Score
Entire Study Cohort (N=2635)



AF Duration Score
Patients with AF Recurrence (N=799)



AF Frequency Score
Entire Study Cohort (N=2635)



AF Frequency Score
Patients with AF Recurrence (N=799)

